In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma, with a price target of $35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andrew Fein’s rating is based on several promising developments within Catalyst Pharma’s operations and market positioning. One of the key factors is the anticipated growth in the use of Firdapse for cancer-associated Lambert-Eaton Myasthenic Syndrome (LEMS), which is expected to become a significant driver of revenue starting in 2026. Currently, only a small percentage of cancer-associated LEMS patients are diagnosed, presenting a substantial opportunity for growth as Catalyst Pharma works to improve diagnosis rates through initiatives like VGCC antibody screening tests and collaborations with oncology networks.
Additionally, the company has reported strong revenue growth, driven by the successful launch of Agamree and better-than-expected performance of Fycompa despite impending generic competition. Agamree’s uptake has exceeded expectations, with significant adoption across major healthcare providers and high reimbursement approval rates. This robust performance, alongside strategic focus on provider education and payer engagement, supports the view that Catalyst Pharma is well-positioned for sustained value creation in both the near and long term.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $33.00 price target.